GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma

GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma

Submitted by admin on October 4, 2019 - 9:59am
Source: 
Pharmaceutical Business Review
News Tags: 
GSK
Innoviva
Trelegy Ellipta
asthma
Headline: 
GSK, Innoviva file sNDA to seek US approval for Trelegy Ellipta in asthma
snippet: 


GlaxoSmithKline (GSK) and Innoviva have filed an application for their respiratory drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) in the US seeking its use for the treatment of asthma in adults.

Do Not Allow Advertisers to Use My Personal information